New platelet booster could keep cancer treatments on track
NCT ID NCT07185893
First seen Nov 01, 2025 · Last updated Apr 26, 2026 · Updated 24 times
Summary
This study tests a drug called romiplostim N01 in cancer patients whose platelet levels drop too low during chemotherapy and radiation. Low platelets can force delays or dose cuts in cancer treatment. The trial compares romiplostim N01 to a standard drug (interleukin-11) to see which works better at raising platelet counts and reducing the need for platelet transfusions. About 106 adults with solid tumors will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.